Publication Date
1-9-2023
Journal
Cancer Cefl
DOI
10.1016/j.ccell.2022.12.001
PMID
36563681
PMCID
PMC9839644
PubMedCentral® Posted Date
1-9-2024
PubMedCentral® Full Text Version
Author MSS
Published Open-Access
yes
Keywords
Humans, Carcinoma, Renal Cell, Kidney Neoplasms, Proteogenomics, Treatment Outcome, Prognosis, Biomarkers, Tumor, clear cell renal cell carcinoma (ccRCC), proteomics, proteogenomics, glycoproteomics, phosphoproteomics, tumor heterogeneity, histology, methylation, metabolome, single nuclei RNA-seq, CPTAC, UCHL1
Abstract
Clear cell renal cell carcinomas (ccRCCs) represent ∼75% of RCC cases and account for most RCC-associated deaths. Inter- and intratumoral heterogeneity (ITH) results in varying prognosis and treatment outcomes. To obtain the most comprehensive profile of ccRCC, we perform integrative histopathologic, proteogenomic, and metabolomic analyses on 305 ccRCC tumor segments and 166 paired adjacent normal tissues from 213 cases. Combining histologic and molecular profiles reveals ITH in 90% of ccRCCs, with 50% demonstrating immune signature heterogeneity. High tumor grade, along with BAP1 mutation, genome instability, increased hypermethylation, and a specific protein glycosylation signature define a high-risk disease subset, where UCHL1 expression displays prognostic value. Single-nuclei RNA sequencing of the adverse sarcomatoid and rhabdoid phenotypes uncover gene signatures and potential insights into tumor evolution. In vitro cell line studies confirm the potential of inhibiting identified phosphoproteome targets. This study molecularly stratifies aggressive histopathologic subtypes that may inform more effective treatment strategies.
Graphical Abstract
Included in
Biological Phenomena, Cell Phenomena, and Immunity Commons, Biomedical Informatics Commons, Genetics and Genomics Commons, Medical Genetics Commons, Medical Molecular Biology Commons, Neoplasms Commons, Oncology Commons